William J He1,2, Jingsha Chen1,2, Alexander C Razavi3,4, Emily A Hu1,2, Morgan E Grams1,2,5, Bing Yu6, Chirag R Parikh1,2,5, Eric Boerwinkle6, Lydia Bazzano3,4, Lu Qi3,4, Tanika N Kelly3, Josef Coresh1,2, Casey M Rebholz7,2,5. 1. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana. 4. Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana. 5. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 6. Department of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health School of Public Health, Houston, Texas. 7. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland crebhol1@jhu.edu.
Abstract
BACKGROUND AND OBJECTIVES: Moderate coffee consumption has been associated with lower risk of CKD; however, the exact biologic mechanisms underlying this association are unknown. Metabolomic profiling may identify metabolic pathways that explain the association between coffee and CKD. The goal of this study was to identify serum metabolites associated with coffee consumption and examine the association between these coffee-associated metabolites and incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using multivariable linear regression, we identified coffee-associated metabolites among 372 serum metabolites available in two subsamples of the Atherosclerosis Risk in Communities study (ARIC; n=3811). Fixed effects meta-analysis was used to pool the results from the two ARIC study subsamples. Associations between coffee and metabolites were replicated in the Bogalusa Heart Study (n=1043). Metabolites with significant associations with coffee in both cohorts were then evaluated for their prospective associations with incident CKD in the ARIC study using Cox proportional hazards regression. RESULTS: In the ARIC study, mean (SD) age was 54 (6) years, 56% were daily coffee drinkers, and 32% drank >2 cups per day. In the Bogalusa Heart Study, mean (SD) age was 48 (5) years, 57% were daily coffee drinkers, and 38% drank >2 cups per day. In a meta-analysis of two subsamples of the ARIC study, 41 metabolites were associated with coffee consumption, of which 20 metabolites replicated in the Bogalusa Heart Study. Three of these 20 coffee-associated metabolites were associated with incident CKD in the ARIC study. CONCLUSIONS: We detected 20 unique serum metabolites associated with coffee consumption in both the ARIC study and the Bogalusa Heart Study, and three of these 20 candidate biomarkers of coffee consumption were associated with incident CKD. One metabolite (glycochenodeoxycholate), a lipid involved in primary bile acid metabolism, may contribute to the favorable kidney health outcomes associated with coffee consumption. Two metabolites (O-methylcatechol sulfate and 3-methyl catechol sulfate), both of which are xenobiotics involved in benzoate metabolism, may represent potential harmful aspects of coffee on kidney health.
BACKGROUND AND OBJECTIVES: Moderate coffee consumption has been associated with lower risk of CKD; however, the exact biologic mechanisms underlying this association are unknown. Metabolomic profiling may identify metabolic pathways that explain the association between coffee and CKD. The goal of this study was to identify serum metabolites associated with coffee consumption and examine the association between these coffee-associated metabolites and incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using multivariable linear regression, we identified coffee-associated metabolites among 372 serum metabolites available in two subsamples of the Atherosclerosis Risk in Communities study (ARIC; n=3811). Fixed effects meta-analysis was used to pool the results from the two ARIC study subsamples. Associations between coffee and metabolites were replicated in the Bogalusa Heart Study (n=1043). Metabolites with significant associations with coffee in both cohorts were then evaluated for their prospective associations with incident CKD in the ARIC study using Cox proportional hazards regression. RESULTS: In the ARIC study, mean (SD) age was 54 (6) years, 56% were daily coffee drinkers, and 32% drank >2 cups per day. In the Bogalusa Heart Study, mean (SD) age was 48 (5) years, 57% were daily coffee drinkers, and 38% drank >2 cups per day. In a meta-analysis of two subsamples of the ARIC study, 41 metabolites were associated with coffee consumption, of which 20 metabolites replicated in the Bogalusa Heart Study. Three of these 20 coffee-associated metabolites were associated with incident CKD in the ARIC study. CONCLUSIONS: We detected 20 unique serum metabolites associated with coffee consumption in both the ARIC study and the Bogalusa Heart Study, and three of these 20 candidate biomarkers of coffee consumption were associated with incident CKD. One metabolite (glycochenodeoxycholate), a lipid involved in primary bile acid metabolism, may contribute to the favorable kidney health outcomes associated with coffee consumption. Two metabolites (O-methylcatechol sulfate and 3-methyl catechol sulfate), both of which are xenobiotics involved in benzoate metabolism, may represent potential harmful aspects of coffee on kidney health.
Authors: Alexander Khoruts; Michael J Sadowsky; Christopher Staley; Alexa R Weingarden Journal: Appl Microbiol Biotechnol Date: 2016-11-25 Impact factor: 4.813
Authors: Casey M Rebholz; Aditya Surapaneni; Andrew S Levey; Mark J Sarnak; Lesley A Inker; Lawrence J Appel; Josef Coresh; Morgan E Grams Journal: J Nutr Date: 2019-04-01 Impact factor: 4.798
Authors: Casey M Rebholz; Deidra C Crews; Morgan E Grams; Lyn M Steffen; Andrew S Levey; Edgar R Miller; Lawrence J Appel; Josef Coresh Journal: Am J Kidney Dis Date: 2016-08-09 Impact factor: 8.860
Authors: Dong Hang; Oana A Zeleznik; Xiaosheng He; Marta Guasch-Ferre; Xia Jiang; Jun Li; Liming Liang; A Heather Eliassen; Clary B Clish; Andrew T Chan; Zhibin Hu; Hongbing Shen; Kathryn M Wilson; Lorelei A Mucci; Qi Sun; Frank B Hu; Walter C Willett; Edward L Giovannucci; Mingyang Song Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112
Authors: Ioanna Tzoulaki; Timothy M D Ebbels; Ana Valdes; Paul Elliott; John P A Ioannidis Journal: Am J Epidemiol Date: 2014-06-24 Impact factor: 4.897
Authors: Emily A Hu; Cheryl A M Anderson; Deidra C Crews; Katherine T Mills; Jiang He; Haochang Shou; Jonathon J Taliercio; Madhumita J Mohanty; Zeenat Bhat; Josef Coresh; Lawrence J Appel; Casey M Rebholz Journal: Curr Dev Nutr Date: 2020-05-21